MedPath

Gadoteric acid

Generic Name
Gadoteric acid
Brand Names
Dotarem
Drug Type
Small Molecule
Chemical Formula
C16H25GdN4O8
CAS Number
72573-82-1
Unique Ingredient Identifier
QVF9Y6955W
Background

Gadoteric acid is a macrocycle-structured gadolinium-based MRI contrast agent. It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). As a paramagnetic molecule, gadoterate develops a magnetic moment when placed in a magnetic field. This magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. More specifically, it reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility. Increased signal brightness allows it to be used in imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'.

Gadoteric acid, as the FDA approved product Dotarem, is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Indication

Gadoteric acid is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.

Phase 2
Recruiting
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
First Posted Date
2024-12-12
Last Posted Date
2024-12-12
Lead Sponsor
IC TARGETS AS
Target Recruit Count
42
Registration Number
NCT06731738
Locations
🇳🇴

Oslo University Hospital, Department of Cardiology, Rikshospitalet Sognsvannsveien 20, Oslo, Norway

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Phase 1
Not yet recruiting
Conditions
Alzheimer Disease, Early Onset
Interventions
Device: Neuronavigation-guided single-element focused ultrasound transducer
Other: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
Radiation: Positron Emission Tomography (PET)
Diagnostic Test: Blood draw
Device: UR5e
Diagnostic Test: Urine test
First Posted Date
2024-09-19
Last Posted Date
2025-05-11
Lead Sponsor
Columbia University
Target Recruit Count
6
Registration Number
NCT06600880
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Advanced Imaging for Pulmonary Fibrosis

Phase 2
Recruiting
Conditions
Pulmonary Fibrosis
Interventions
First Posted Date
2024-08-01
Last Posted Date
2025-03-26
Lead Sponsor
Peter Caravan
Target Recruit Count
60
Registration Number
NCT06532071
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas

Phase 3
Completed
Conditions
Brain Tumor, Recurrent
Brain Tumor, Primary
Interventions
First Posted Date
2023-09-28
Last Posted Date
2025-05-06
Lead Sponsor
Guerbet
Target Recruit Count
138
Registration Number
NCT06057168
Locations
🇭🇺

Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá, Budapest, Hungary

🇭🇺

Semmelweis Egyetem - Neurologiai Klinika, Budapest, Hungary

🇭🇺

Debreceni Egyetem, Debrecen, Hungary

and more 8 locations

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Phase 3
Completed
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Non-central Nervous System Pathology
Interventions
First Posted Date
2023-06-23
Last Posted Date
2025-05-08
Lead Sponsor
Bayer
Target Recruit Count
404
Registration Number
NCT05915728
Locations
🇨🇿

Fakultni nemocnice Plzen - Lochotin, Plzen, Czechia

🇦🇷

Sanatorio Allende | Departamento de Investigación Clínica, Córdoba, Argentina

🇫🇷

Hôpital Bichat Claude Bernard - Service de radiologie, Paris, France

and more 82 locations

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Phase 3
Completed
Conditions
Central Nervous System Pathology
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
First Posted Date
2023-06-23
Last Posted Date
2025-05-08
Lead Sponsor
Bayer
Target Recruit Count
303
Registration Number
NCT05915702
Locations
🇨🇿

Fakultni nemocnice Plzen - Lochotin, Plzen, Czechia

🇭🇺

Szent Damjan Gorogkatolikus Korhaz, Kisvarda, Hungary

🇭🇺

Idegsebeszeti Klinika, Pecs, Hungary

and more 75 locations

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Phase 2
Recruiting
Conditions
Interstitial Lung Disease
Interventions
First Posted Date
2022-06-14
Last Posted Date
2025-05-09
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
30
Registration Number
NCT05417776
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Phase 4
Recruiting
Conditions
Motor Function
Cognitive Function
Contrast Media
Interventions
Procedure: Motor Tests
Procedure: Cognitive Tests
Procedure: Unenhanced-MRI of the brain
Procedure: Gadolinium Measurements
First Posted Date
2020-05-04
Last Posted Date
2024-05-17
Lead Sponsor
Guerbet
Target Recruit Count
2076
Registration Number
NCT04373564
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

🇧🇷

Hospital Santa Marta, Taguatinga, Distrito Federal, Brazil

and more 43 locations

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

Completed
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
First Posted Date
2019-04-10
Last Posted Date
2019-04-10
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
500
Registration Number
NCT03910114
Locations
🇺🇸

Vanderbilt Childeen's Hospital, Nashville, Tennessee, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Dotarem vs Gadobutrol Contrast for Breast MRI

Phase 4
Recruiting
Conditions
Breast Diseases
Interventions
First Posted Date
2018-11-05
Last Posted Date
2025-04-02
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
258
Registration Number
NCT03730051
Locations
🇺🇸

UMass Medical School, Worcester, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath